{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:00:11Z","timestamp":1776776411045,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00406-019-01005-0","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T15:02:41Z","timestamp":1553785361000},"page":"851-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic correlates of venlafaxine: associated adverse reactions"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Endres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Ridders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Veselinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","volume":"20","author":"SM Fogelman","year":"1999","unstructured":"Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and n-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cdna-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480\u2013490","journal-title":"Neuropsychopharmacology"},{"key":"1005_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","volume":"32","author":"KJ Klamerus","year":"1992","unstructured":"Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST (1992) Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active o-desmethyl metabolite. J Clin Pharmacol 32:716\u2013724","journal-title":"J Clin Pharmacol"},{"key":"1005_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9\u201362","journal-title":"Pharmacopsychiatry"},{"key":"1005_CR4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JCP.0000000000000344","volume":"35","author":"D Abadie","year":"2015","unstructured":"Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F (2015) Serotonin syndrome: analysis of cases registered in the french pharmacovigilance database. J Clin Psychopharmacol 35:382\u2013388","journal-title":"J Clin Psychopharmacol"},{"issue":"10128","key":"1005_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357\u20131366","journal-title":"Lancet"},{"key":"1005_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0165-0327(98)00222-5","volume":"51","author":"WD Horst","year":"1998","unstructured":"Horst WD, Preskorn SH (1998) Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237\u2013254","journal-title":"J Affect Disord"},{"key":"1005_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00414-010-0461-5","volume":"125","author":"T Launiainen","year":"2011","unstructured":"Launiainen T, Rasanen I, Vuori E, Ojanpera I (2011) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Leg Med 125:349\u2013358","journal-title":"Int J Leg Med"},{"key":"1005_CR8","doi-asserted-by":"publisher","first-page":"e90453","DOI":"10.1371\/journal.pone.0090453","volume":"9","author":"A Sicras-Mainar","year":"2014","unstructured":"Sicras-Mainar A, Guijarro P, Armada B, Blanca-Tamayo M, Navarro-Artieda R (2014) Influence of the cyp2d6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One 9:e90453","journal-title":"PLoS One"},{"key":"1005_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/15563650.2012.763133","volume":"51","author":"M Batista","year":"2013","unstructured":"Batista M, Dugernier T, Simon M, Haufroid V, Capron A, Fonseca S, Bonbled F, Hantson P (2013) The spectrum of acute heart failure after venlafaxine overdose. Clin Toxicol 51:92\u201395","journal-title":"Clin Toxicol"},{"key":"1005_CR10","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/j.forsciint.2016.05.030","volume":"266","author":"D Castanares-Zapatero","year":"2016","unstructured":"Castanares-Zapatero D, Gillard N, Capron A, Haufroid V, Hantson P (2016) Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism. Forensic Sci Int 266:e48\u2013e51","journal-title":"Forensic Sci Int"},{"key":"1005_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FTD.0b013e31828816e0","volume":"35","author":"C Geber","year":"2013","unstructured":"Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadic A (2013) Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Ther Drug Monit 35:279\u2013282","journal-title":"Ther Drug Monit"},{"key":"1005_CR12","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.forsciint.2012.12.020","volume":"226","author":"J Jornil","year":"2013","unstructured":"Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LW, Brock B (2013) A poor metabolizer of both cyp2c19 and cyp2d6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 226:e26\u2013e31","journal-title":"Forensic Sci Int"},{"key":"1005_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00134-006-0419-8","volume":"33","author":"B Megarbane","year":"2007","unstructured":"Megarbane B, Bloch V, Deye N, Baud FJ (2007) Pharmacokinetic\/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose. Intensive Care Med 33:195\u2013196","journal-title":"Intensive Care Med"},{"key":"1005_CR14","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00213-014-3825-6","volume":"232","author":"F Jiang","year":"2015","unstructured":"Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, Ha JH, Shin HJ, Kim YH, Chung MW (2015) The influences of cyp2d6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology 232:1899\u20131909","journal-title":"Psychopharmacology"},{"key":"1005_CR15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/JCP.0000000000000336","volume":"35","author":"S Unterecker","year":"2015","unstructured":"Unterecker S, Pfuhlmann B, Kopf J, Kittel-Schneider S, Reif A, Deckert J (2015) Increase of heart rate and QTC by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol 35:460\u2013463","journal-title":"J Clin Psychopharmacol"},{"key":"1005_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1055\/s-0044-102009","volume":"52","author":"G Hefner","year":"2019","unstructured":"Hefner G, Hahn M, Hohner M, Roll SC, Klimke A, Hiemke C (2019) QTC time correlates with amitriptyline and venlafaxine serum levels in elderly psychiatric inpatients. Pharmacopsychiatry 52:38\u201343","journal-title":"Pharmacopsychiatry"},{"key":"1005_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","volume":"31","author":"ME Shams","year":"2006","unstructured":"Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S (2006) Cyp2d6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493\u2013502","journal-title":"J Clin Pharm Ther"},{"key":"1005_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/08039488.2016.1268203","volume":"71","author":"G Ozbey","year":"2017","unstructured":"Ozbey G, Celikel FC, Cumurcu BE, Kan D, Yucel B, Hasbek E, Percin F, Guzey IC, Uluoglu C (2017) Influence of abcb1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder. Nord J Psychiatry 71:230\u2013237","journal-title":"Nord J Psychiatry"},{"key":"1005_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1055\/s-0031-1284428","volume":"44","author":"T Neuner","year":"2011","unstructured":"Neuner T, Hubner-Liebermann B, Haen E, Hausner H, Felber W, Wittmann M, Agate (2011) Completed suicides in 47 psychiatric hospitals in Germany\u2014results from the agate-study. Pharmacopsychiatry 44:324\u2013330","journal-title":"Pharmacopsychiatry"},{"key":"1005_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000135641","volume":"57","author":"D Fischer-Barnicol","year":"2008","unstructured":"Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE, Working Group \u2018Drugs in P (2008) Typical and atypical antipsychotics\u2014the misleading dichotomy. Results from the working group \u2018drugs in psychiatry\u2019 (agate). Neuropsychobiology 57:80\u201387","journal-title":"Neuropsychobiology"},{"key":"1005_CR21","unstructured":"US Food & Drug Administration (2014) Drug development and drug interactions: table of substrates, inhibitors and inducers. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm . Accessed 30 Jan 2019"},{"key":"1005_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The uku side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1\u2013100","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"1005_CR23","first-page":"142","volume":"76","author":"L Paul","year":"2009","unstructured":"Paul L, Musshoff F, Aebi B, Auw\u00e4rter V, Kr\u00e4mer T, Peters F, Skopp G, Aderjan R, Herbold M, Schmitt G (2009) Richtlinie der gtfch zur qualit\u00e4tssicherung bei forensisch-toxikologischen untersuchungen. Toxichem Krimtech 76:142\u2013176","journal-title":"Toxichem Krimtech"},{"key":"1005_CR24","unstructured":"US Food & Drug Administration (2001) Guidance for industry on biomedical method validation. http:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm070107.pdf . Accessed 30 Jan 2019"},{"key":"1005_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4088\/JCP.12m07807","volume":"74","author":"SH Preskorn","year":"2013","unstructured":"Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ (2013) Cytochrome p450 2d6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 74:614\u2013621","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1005_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/YIC.0000000000000234","volume":"33","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Haen E, Hiemke C, Fay B, Unholzer S, Correll CU, Grunder G, Paulzen M (2018) Sex and body weight are major determinants of venlafaxine pharmacokinetics. Int Clin Psychopharmacol 33(6):322\u2013329","journal-title":"Int Clin Psychopharmacol"},{"key":"1005_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","volume":"24","author":"M Reis","year":"2002","unstructured":"Reis M, Lundmark J, Bjork H, Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 24:545\u2013553","journal-title":"Ther Drug Monit"},{"key":"1005_CR28","first-page":"6236714","volume":"2017","author":"S Garcia","year":"2017","unstructured":"Garcia S, Schuh M, Cheema A, Atwal H, Atwal PS (2017) Palpitations and asthenia associated with venlafaxine in a cyp2d6 poor metabolizer and cyp2c19 intermediate metabolizer. Case Rep Genet 2017:6236714","journal-title":"Case Rep Genet"},{"key":"1005_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1258\/acb.2009.009003","volume":"46","author":"PA Wijnen","year":"2009","unstructured":"Wijnen PA, Limantoro I, Drent M, Bekers O, Kuijpers PM, Koek GH (2009) Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking cyp2d6 activity. Ann Clin Biochem 46:527\u2013530","journal-title":"Ann Clin Biochem"},{"key":"1005_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","volume":"31","author":"M Reis","year":"2009","unstructured":"Reis M, Aamo T, Spigset O, Ahlner J (2009) Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 31:42\u201356","journal-title":"Ther Drug Monit"},{"key":"1005_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00213-010-2148-5","volume":"215","author":"L Karlsson","year":"2011","unstructured":"Karlsson L, Hiemke C, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, Schmitt U, Kugelberg FC (2011) Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the p-glycoprotein knockout mice model. Psychopharmacology 215:367\u2013377","journal-title":"Psychopharmacology"},{"key":"1005_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/tpj.2014.50","volume":"15","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, Zackrisson AL, Josefsson M, Carlsson B, Green H, Kugelberg FC (2015) Influence of cyp2d6 and cyp2c19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases. Pharmacogenom J 15:165\u2013171","journal-title":"Pharmacogenom J"},{"key":"1005_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/FPC.0b013e328363688d","volume":"23","author":"EW Chua","year":"2013","unstructured":"Chua EW, Foulds J, Miller AL, Kennedy MA (2013) Novel cyp2d6 and cyp2c19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine. Pharmacogenet Genom 23:494\u2013497","journal-title":"Pharmacogenet Genom"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-01005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-019-01005-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-01005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T17:57:13Z","timestamp":1663178233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-019-01005-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s00406-019-01005-0","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Georgios Schoretsanitis received a grant from the bequest \u201cin memory of Maria Zaoussi\u201d, State Scholarships Foundation, Greece for clinical research in Psychiatry for the academic year 2015\u20132016. Ekkehard Haen received speaker\u2019s or consultancy fees from the following pharmaceutical companies: Servier, Novartis, and Janssen-Cilag. He is the managing director of AGATE, a non-profit working group to improve drug safety and efficacy in the treatment of psychiatric diseases. He reports no conflict of interest with this publication. Christoph Hiemke has received speaker\u2019s or consultancy fees from the following pharmaceutical companies: Astra Zeneca, Janssen-Cilag, Pfizer, Lilly and Servier. He is managing director of the psiac GmbH which provides an internet-based drug\u2013drug interaction program for psychopharmacotherapy. He reports no conflict of interest with this publication. Gerhard Gr\u00fcnder has served as a consultant for Allergan (Dublin, Ireland), Boehringer Ingelheim (Ingelheim, Germany), Eli Lilly (Indianapolis, Ind, USA), Janssen-Cilag (Neuss, Germany), Lundbeck (Copenhagen, Denmark), Ono Pharmaceuticals (Osaka, Japan), Otsuka (Chiyoda, Japan), Recordati (Milan, Italy), Roche (Basel, Switzerland), Servier (Paris, France), and Takeda (Osaka, Japan). He has served on the speakers\u2019 bureau of Eli Lilly, Janssen Cilag, Neuraxpharm (Langenfeld, Germany), Lundbeck, Otsuka, Recordati, Roche, Servier, and Trommsdorf (Aachen, Germany). He has received grant support from Boehringer Ingelheim and Roche. He is co-founder of Mind and Brain Institute GmbH (Zornheim, Germany) and Brainfoods GmbH (Zornheim, Germany). He reports no conflict of interest with this publication. All other authors declare no conflicts of interest as well.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research work was conducted in accordance with the Code of Ethics of the World Medical Association and the local regulatory authority of RWTH Aachen University hospital. No sources of funding were provided for this project. No potential conflicts of interest are reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}